Article Text

PDF
Letters
Prostaglandin E1 use during neonatal transfer: potential beneficial role in persistent pulmonary hypertension of the newborn
  1. Neelam Gupta1,2,
  2. C Omar Kamlin1,3,4,
  3. Michael Cheung5,
  4. Michael Stewart1,
  5. Neil Patel6
  1. 1Newborn Emergency Transport Services, Royal Children's Hospital, Melbourne, Australia
  2. 2Neonatal Unit, John Radcliffe Hospital, Oxford, UK
  3. 3Division of Newborn Services, Royal Women's Hospital, Melbourne, Australia
  4. 4The University of Melbourne, Melbourne, Australia
  5. 5Department of Paediatric Cardiology, Royal Children's Hospital, Melbourne, Australia
  6. 6Neonatal Unit, Royal Children's Hospital, Melbourne, Australia
  1. Correspondence to Dr Neelam Gupta, Neonatal Unit, Level 2, Women's Centre, John Radcliffe Hospital, Oxford OX39DU, UK; neelam27{at}doctors.org.uk

Statistics from Altmetric.com

Distinguishing duct dependent congenital heart disease (DDCHD) from other causes of hypoxaemia, notably persistent pulmonary hypertension (PPHN), represents a diagnostic and therapeutic dilemma for neonatal transport teams, specifically in relation to use of prostaglandin E1 (PGE1). In non-DDCHD, PGE1 is considered unnecessary and likely to produce unwanted side-effects including apnoea and hypotension.1

We report our observations of the effects of PGE1 infusion in a group of babies with evidence of PPHN but without DDCHD.

We reviewed the data on all infants ≤10 days and ≥34 weeks gestation with suspected DDCHD and/or PPHN transferred by the Newborn Emergency Transport Service (NETS), Victoria, from non-tertiary neonatal units to the regional paediatric cardiac …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.